AI-powered microbiome models for personalized therapeutic design
OurVision
Today, drugs are designed for populations, not individuals. Even the best therapies work for some and fail for many, making treatment a process of trial and error. The human microbiome is a key, yet largely unaccounted for, driver of how individuals respond to treatment.
Tinuviel Therapeutics is building AI-powered microbiome models to simulate drug response and design therapies for each individual, replacing trial-and-error with precision by design.
The world’s first digital twin of the human microbiome, powered by breakthrough technology
OurPlatform
Tinuviel is building an integrated software platform to simulate and optimize therapeutic response at the level of the individual, replacing trial-and-error with precision by design.
Microbiome Digital Twin
The Right Therapy, Designed for Every Individual
Tinuviel’s AI-powered microbiome digital twins model how past exposures such as drugs, diet, and disease shape individual treatment response. Unlike traditional approaches that rely on static snapshots, our platform simulates the microbiome as a dynamic, medical history-aware system. By integrating multi-omic and longitudinal data, these models enable in silico testing of therapies, counterfactual analysis, and optimization of treatment strategies providing a predictive foundation for personalized medicine.
HospitalsHealth Insurance Companies
Microbiome Resilience Index (MRI)
Quantifying Microbiome Health and Risk
The Microbiome Resilience Index (MRI) translates digital twin simulations into a scalable, clinically actionable measure of microbiome health. By distilling complex, medical history-dependent dynamics into interpretable metrics, such as recovery capacity, robustness to stress, and risk of system failure, MRI enables comparison across individuals, life stages, and treatment scenarios. This allows early identification of at-risk patients, supports population-scale screening, and bridges high-fidelity simulation with real-world clinical decision-making.
HospitalsHealth Insurance Companies
Algorithmic Therapeutic Design Platform
Precision Intervention Design
Building on the digital twin and MRI, Tinuviel’s platform designs personalized interventions to protect, and restore microbiome health. By combining an individual’s microbiome state, medical history, and clinical context, the system identifies minimal, safe combinations of bacterial strains and nutrients to prevent disruption or restore function. Through advanced optimization, the platform generates clinically actionable therapeutic strategies enabling precision intervention design at scale.
Pharmaceutical Companies
OurTechnology
Tinuviel’s platform combines data-driven AI with mechanistic models to accurately simulate how individuals respond to therapy. By embedding biological constraints directly into the modeling framework, we achieve superior robustness, interpretability, and data efficiency compared to black-box approaches.
Leveraging hybrid quantum–classical computing for complex optimization, the platform enables simulation and design of therapeutic strategies across diverse biological contexts. This integrated approach enables the design of personalized therapies at scale shifting drug development from trial-and-error to precision by design.
About
Tinuviel Therapeutics is building the computational foundation for personalized medicine.
Founded at the intersection of cutting-edge microbiome science and advanced computation, Tinuviel is redefining how therapies are designed, shifting from trial-and-error to engineered precision. By enabling predictive, microbiome simulation-driven treatment design, Tinuviel aims to unlock more effective therapies, reduce development risk, and deliver truly individualized care at scale.
Leadership Team
Timur Tuganbaev, PhD
Founder and CEOTimur Tuganbaev is the Founder and CEO of Tinuviel Therapeutics, where he leads the company’s mission to transform treatment from trial-and-error to precision by design. He holds a PhD in immunology from the Weizmann Institute of Science and is a microbiome scientist with deep expertise in host–microbiome interactions, immune regulation, and disease biology.
Timur has authored and co-authored publications in leading journals including Nature, Cell, and Science, contributing to foundational advances in understanding how microbial dynamics shape human health and therapeutic response.
At Tinuviel, Timur is pioneering the integration of microbiome science with AI-driven modeling to build scalable microbiome digital twins. His vision is to enable predictive, simulation-based therapeutic design, unlocking personalized treatments for each individual and creating a new paradigm in precision medicine.
Ryan Browne
CTORyan is a multidisciplinary technology leader working at the intersection of medicine and advanced computation. He holds an M.Sci. in Chemistry with Molecular Physics from Imperial College London and an M.Sc. in Basic Medical Science from Tohoku University.
He has co-authored 18 publications across medical science and aging, with work featured in journals including Nature Communications Biology and Cerebral Cortex. He has secured competitive funding and led international teams delivering high-impact results across AI, human-computer interaction, and biomedical research.
As CTO of Tinuviel Therapeutics, Ryan leads the development of AI-powered microbiome digital twins to model individual treatment response. He integrates data-driven AI with mechanistic modeling and emerging quantum–classical approaches to enable predictive, simulation-based therapeutic design at scale.
